3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
15
Urinary Bladder Neoplasms
14
Carcinoma, Transitional Cell
14
Neoplasms
5
Urologic Neoplasms
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Neoplasms by Site
3
Carcinoma
3
Recurrence
2
Carcinoma in Situ
2
Virus Diseases
1
Urogenital Diseases
1
Neoplasms by Histologic Type
1
Neoplasm Recurrence, Local
1
Mycobacterium Infections
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Disease
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
motexafin gadolinium
1
Talaporfin
1
Rhenium
1
Poly I-C
1
Mitomycin
1
Lomustine
1
Folfox protocol
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm Recurrence, Local
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts